Terminal nucleotidyltransferase 5A (TENT5A)

Terminal nucleotidyltransferase 5A (TENT5A) is a cytoplasmic non-canonical poly(A) RNA polymerase that catalyzes the addition of adenosine monophosphate to the 3' ends of ER-targeted mRNAs, primarily facilitating cytoplasmic polyadenylation and stabilization of transcripts encoding extracellular matrix and bone mineralization proteins. TENT5A acts as a tumor suppressor in hepatocellular carcinoma by repressing mTOR pathway signaling, and its expression is positively regulated by the transcription factor EGR1. Mutations or reduced function of TENT5A are causative of osteogenesis imperfecta type XVIII and have been linked to retinitis pigmentosa, obesity, and other pathological states[1][2][6]. Note: - No approved drugs directly target TENT5A yet. - No mechanism of action or safety profile for TENT5A-directed therapeutics exists as of the latest available data. - TENT5A is a validated molecular disease gene but not an established drug target in clinical pharmacology at this time.

Other names

C6orf37FAM46AFLJ20037HBV X-transactivated gene 11 proteinHBV XAg-transactivated protein 11OI18XTP11family with sequence similarity 46 member Aprotein FAM46Aretinal expressed gene C6orf37putative nucleotidyltransferase FAM46ABAP014D930050G01RikRGD1311381